Suppr超能文献

健康权诉讼与药品获取:哥斯达黎加最高法院宪法庭成功案例的优先分类

Health rights litigation and access to medicines: priority classification of successful cases from Costa Rica's constitutional chamber of the Supreme Court.

作者信息

Norheim Ole Frithjof, Wilson Bruce M

机构信息

Professor in the Department of Global Public Health and Primary Care, University of Bergen,Norway.

Professor in the Department of Political Science at the University of Central Florida, Orlando, FL, USA, and Associated Senior Researcher at the Chr. Michelsen Institute, Bergen, Norway.

出版信息

Health Hum Rights. 2014 Dec 11;16(2):E47-61.

Abstract

Although Costa Rica has no explicit constitutional right to health, its constitutional chamber of the Supreme Court (Sala IV) has become increasingly central to the resolution of many health care decisions. Some argue that courts' decisions about individuals' access to very expensive medications could upset the country's medical priorities and harm the state's general health care provision capacity. This article assesses whether health rights litigation concerning the right to medications leads to more fairness in access to medications in Costa Rica. We review randomly selected access to medicines cases successfully claimed at the Sala IV in 2008 and classify them into four priority groups using standard priority-setting criteria. We find that 2.7% of the successful cases fall into priority group I (highest priority), 27% in group II, 48.6% in group III, and 21.6% in group IV (experimental treatment). Our analysis reveals a majority of successful health rights litigation for medications results in court-mandated provision of new, expensive drugs, many with only marginal benefits. More than 70% of the successful cases evaluated concerned medications judged to be of low priority. Based on these cases, we cannot conclude that litigation leads to more fairness in access to medications.

摘要

尽管哥斯达黎加宪法中没有明确的健康权,但该国最高法院宪法法庭(第四法庭)在许多医疗保健决策的解决中变得越来越核心。一些人认为,法院关于个人获取非常昂贵药物的决定可能会扰乱该国的医疗优先事项,并损害国家的总体医疗保健提供能力。本文评估了哥斯达黎加有关药物权的健康权诉讼是否会使药物获取更加公平。我们回顾了2008年在第四法庭成功索赔的随机选择的药物获取案例,并使用标准的优先排序标准将它们分为四个优先组。我们发现,2.7%的成功案例属于第一优先组(最高优先级),27%属于第二组,48.6%属于第三组,21.6%属于第四组(实验性治疗)。我们的分析表明,大多数成功的药物健康权诉讼导致法院强制提供新的、昂贵的药物,其中许多药物的益处微乎其微。超过70%的评估成功案例涉及被判定为低优先级的药物。基于这些案例,我们不能得出诉讼会使药物获取更加公平的结论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验